Eplerenone

Initiation of the nonsteroidal mineralocorticoid receptor antagonist eplerenone shows benefit in patients with HF with reduced ejection fraction, regardless of their disease duration, 1 year or more than 5 years, a speaker reported.

Central serous retinopathy occurs in middle-age adults, typically spontaneously, and is associated with accumulation of fluid below the retina. It can be commonly mistaken for age-related macular degeneration and lacks a unified treatment approach. The common treatment for acute central serous is observation. However, for central serous lasting longer than 4 months, the chronicity of disease can lead to photoreceptor loss and damage and ultimately decreased vision.

NEPTUNE, N.J. – A 58-year-old man with distorted vision was diagnosed with central serous chorioretinopathy and was successfully treated with oral eplerenone, 25 mg twice a day, according to Yuyeng Lor, OD, MPH, here at a New Jersey Academy of Optometry continuing education event.